Navigation Links
BRAF inhibitor shows promising preclinical activity against melanoma
Date:6/15/2010

PHILADELPHIA Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity.

BRAF mutations are found in about 8 percent of all solid tumors but in about 50 percent of melanomas.


"Patients with advanced melanoma currently do not have a lot of options. There are some therapies, but the response rates are very low. Based on this promising preclinical data, we believe this compound merits further study in patients with advanced melanoma," said Dave Heimbrook, Ph.D., global head of discovery oncology at Roche and one of the study authors.

The Cancer Research paper is the first published report of RG7204, which shows tumor regressions in preclinical models. Roche and Plexxikon scientists and their academic collaborators have presented Phase I clinical data at medical meetings.

William Pao, M.D., Ph.D., associate professor of medicine, cancer biology and pathology at Vanderbilt University, said this preclinical research represents a significant step forward in establishing a basis for additional study in melanoma patients.

"This drug will have an impact," said Pao. "The response rates with currently available therapies are only in the 10 percent to 20 percent range, so this represents a large step forward."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert  

Page: 1

Related medicine news :

1. Reportlinker Adds Kinase Inhibitors: Global Markets
2. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
3. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
4. Adoodle Donates NOXO Odor Inhibitor Product to Operation USA to Aid Rescue Workers in Haiti
5. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
6. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. Experimental stem cell treatment arrests acute lung injury in mice, study shows
9. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
10. A Study by Celibre Medical Corporation Shows Botox Injections to be the Most Desirable Cosmetic Procedure in Southern California
11. Diabetes patients rank health concerns differently than their doctors, U-M survey shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BRAF inhibitor shows promising preclinical activity against melanoma
(Date:12/10/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) continues ... healthcare organizations to promote diabetes education at the World Diabetes Day observance. The ... speakers from around the Commonwealth of Pennsylvania. Speakers included Dr. Renu Joshi ...
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... When faced ... worried about germs spreading from the seat to her body, and contamination of children ... and effective way to solve this problem that many people face. , The patent-pending ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... Cincinnati, Ohio (PRWEB) , ... December 09, 2016 ... ... production of miniature, folded, pharmaceutical inserts and outserts. As a means of ... This addition will enable Flottman to individually code professional inserts (PIs) and ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... share of the market in 2016 and is expected ... be attributed to a large number of surgical procedures ... the largest share in the patient temperature management market.) ... as reducing loss of blood during surgeries, lowering the ...
Breaking Medicine Technology: